{"transactions":[{"id":2936291,"issuer":{"id":109857,"kind":"organization","name":"Surface Oncology, Inc.","symbol":"SURF"},"owners":[{"id":144498,"kind":"organization","name":"Atlas Venture Fund IX, L.P.","position":1,"cik":"0001671219","reported_name":"Atlas Venture Fund IX, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":144499,"kind":"organization","name":"Atlas Venture Associates IX, L.P.","position":2,"cik":"0001671208","reported_name":"Atlas Venture Associates IX, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":105946,"kind":"organization","name":"Atlas Venture Associates IX, LLC","position":3,"cik":"0001671207","reported_name":"Atlas Venture Associates IX, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2020-12-21T15:35:15.000Z","date":"2020-12-17","kind":"sale","acquired":false,"shares":1700000,"price":8.1,"value":13770000.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents shares sold by Atlas Venture Fund IX, L.P. (\"Atlas IX\").  Atlas Venture Associates IX, L.P. (\"AVA IX LP\") is the general partner of Atlas IX.  Atlas Venture Associates IX, LLC (\"AVA IX LLC\") is the general partner of AVA IX LP.  Each of Atlas IX, AVA IX LP and AVA IX LLC disclaims Section 16 beneficial ownership of the securities held by Atlas IX, except to the extent of their pecuniary interest therein, if any. This report shall not be deemed to an admission that any of the Reporting Persons is the beneficial owner of such securities for purposes of Section 16 or for any other purpose."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The high, low and average for the shares sold were all $8.10.  Each of the Reporting Persons undertake to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in footnote (2) of this Form 4."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"This Amendment to the Form 4 originally filed by the Reporting Persons on December 21, 2020 is filed to amend the share price in Table I from $18.10 to $8.10."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F3","text":"Represents shares held directly by Atlas IX. The general partner of the Atlas IX is AVA IX LP.  AVA IX LLC is the general partner of AVA IX LP. Each of AVA IX LP and AVA IX LLC disclaims Section 16 beneficial ownership of the securities held by the Atlas IX except to the extent of its pecuniary interest therein, if any."}],"balance_after":2945453,"source":{"system":"sec-edgar","filing":"0001104659-20-138021","document":"a4a.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1718108/000110465920138021/a4a.xml","form_type":"4/A","original_submission_date":"2020-12-21"}},{"id":2936289,"issuer":{"id":109857,"kind":"organization","name":"Surface Oncology, Inc.","symbol":"SURF"},"owners":[{"id":144498,"kind":"organization","name":"Atlas Venture Fund IX, L.P.","position":1,"cik":"0001671219","reported_name":"Atlas Venture Fund IX, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":144499,"kind":"organization","name":"Atlas Venture Associates IX, L.P.","position":2,"cik":"0001671208","reported_name":"Atlas Venture Associates IX, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":105946,"kind":"organization","name":"Atlas Venture Associates IX, LLC","position":3,"cik":"0001671207","reported_name":"Atlas Venture Associates IX, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2020-12-21T13:32:27.000Z","date":"2020-12-17","kind":"sale","acquired":false,"shares":1700000,"price":18.1,"value":30770000.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents shares sold by Atlas Venture Fund IX, L.P. (\"Atlas IX\").  Atlas Venture Associates IX, L.P. (\"AVA IX LP\") is the general partner of Atlas IX.  Atlas Venture Associates IX, LLC (\"AVA IX LLC\") is the general partner of AVA IX LP.  Each of Atlas IX, AVA IX LP and AVA IX LLC disclaims Section 16 beneficial ownership of the securities held by Atlas IX, except to the extent of their pecuniary interest therein, if any. This report shall not be deemed to an admission that any of the Reporting Persons is the beneficial owner of such securities for purposes of Section 16 or for any other purpose."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The high, low and average for the shares sold were all $8.10.  Each of the Reporting Persons undertake to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in footnote (2) of this Form 4."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F3","text":"Represents shares held directly by Atlas IX. The general partner of the Atlas IX is AVA IX LP.  AVA IX LLC is the general partner of AVA IX LP. Each of AVA IX LP and AVA IX LLC disclaims Section 16 beneficial ownership of the securities held by the Atlas IX except to the extent of its pecuniary interest therein, if any."}],"balance_after":2945453,"source":{"system":"sec-edgar","filing":"0001104659-20-137966","document":"a4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1718108/000110465920137966/a4.xml","form_type":"4"}},{"id":3958650,"issuer":{"id":109857,"kind":"organization","name":"Surface Oncology, Inc.","symbol":"SURF"},"owners":[{"id":144498,"kind":"organization","name":"Atlas Venture Fund IX, L.P.","position":1,"cik":"0001671219","reported_name":"Atlas Venture Fund IX, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":144499,"kind":"organization","name":"Atlas Venture Associates IX, L.P.","position":2,"cik":"0001671208","reported_name":"Atlas Venture Associates IX, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":105946,"kind":"organization","name":"Atlas Venture Associates IX, LLC","position":3,"cik":"0001671207","reported_name":"Atlas Venture Associates IX, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series A Preferred Stock","published_at":"2018-04-23T16:18:51.000Z","date":"2018-04-23","kind":"exercise","acquired":false,"shares":7000000,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"The Series A Preferred Stock automatically converted into the Issuer's common stock on a 2.2-for-1 basis at the closing of the Issuer's initial public\noffering without payment or further consideration and had no expiration date."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The Series A Preferred Stock automatically converted into the Issuer's common stock on a 2.2-for-1 basis at the closing of the Issuer's initial public\noffering without payment or further consideration and had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The Series A Preferred Stock automatically converted into the Issuer's common stock on a 2.2-for-1 basis at the closing of the Issuer's initial public\noffering without payment or further consideration and had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"The Series A Preferred Stock automatically converted into the Issuer's common stock on a 2.2-for-1 basis at the closing of the Issuer's initial public\noffering without payment or further consideration and had no expiration date."},{"field":"derivative.underlying_shares","element":"underlyingSecurityShares","label":"F1","text":"The Series A Preferred Stock automatically converted into the Issuer's common stock on a 2.2-for-1 basis at the closing of the Issuer's initial public\noffering without payment or further consideration and had no expiration date."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"The shares are held directly by Atlas Venture Fund IX, L.P. (\"Atlas Venture Fund IX\"). The general partner of Atlas Venture Fund IX is Atlas\nVenture Associates IX, L.P. (\"AVA IX LP\"). Atlas Venture Associates IX, LLC (\"AVA IX LLC\") is the general partner of AVA IX LP. Each of AVA\nIX LP and AVA IX LLC disclaims Section 16 beneficial ownership of the securities held by Atlas Venture Fund IX, except to the extent of its\npecuniary interest therein, if any."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":3181817},"source":{"system":"sec-edgar","filing":"0001209191-18-025826","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1718108/000120919118025826/doc4.xml","form_type":"4"}},{"id":3958649,"issuer":{"id":109857,"kind":"organization","name":"Surface Oncology, Inc.","symbol":"SURF"},"owners":[{"id":144498,"kind":"organization","name":"Atlas Venture Fund IX, L.P.","position":1,"cik":"0001671219","reported_name":"Atlas Venture Fund IX, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":144499,"kind":"organization","name":"Atlas Venture Associates IX, L.P.","position":2,"cik":"0001671208","reported_name":"Atlas Venture Associates IX, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":105946,"kind":"organization","name":"Atlas Venture Associates IX, LLC","position":3,"cik":"0001671207","reported_name":"Atlas Venture Associates IX, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2018-04-23T16:18:51.000Z","date":"2018-04-23","kind":"purchase","acquired":true,"shares":100000,"price":15,"value":1500000.0,"ownership":{"direct":true},"footnotes":[{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"The shares are held directly by Atlas Venture Fund IX, L.P. (\"Atlas Venture Fund IX\"). The general partner of Atlas Venture Fund IX is Atlas\nVenture Associates IX, L.P. (\"AVA IX LP\"). Atlas Venture Associates IX, LLC (\"AVA IX LLC\") is the general partner of AVA IX LP. Each of AVA\nIX LP and AVA IX LLC disclaims Section 16 beneficial ownership of the securities held by Atlas Venture Fund IX, except to the extent of its\npecuniary interest therein, if any."}],"balance_after":4645453,"source":{"system":"sec-edgar","filing":"0001209191-18-025826","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1718108/000120919118025826/doc4.xml","form_type":"4"}},{"id":3958648,"issuer":{"id":109857,"kind":"organization","name":"Surface Oncology, Inc.","symbol":"SURF"},"owners":[{"id":144498,"kind":"organization","name":"Atlas Venture Fund IX, L.P.","position":1,"cik":"0001671219","reported_name":"Atlas Venture Fund IX, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":144499,"kind":"organization","name":"Atlas Venture Associates IX, L.P.","position":2,"cik":"0001671208","reported_name":"Atlas Venture Associates IX, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":105946,"kind":"organization","name":"Atlas Venture Associates IX, LLC","position":3,"cik":"0001671207","reported_name":"Atlas Venture Associates IX, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2018-04-23T16:18:51.000Z","date":"2018-04-23","kind":"exercise","acquired":true,"shares":3181817,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The Series A Preferred Stock automatically converted into the Issuer's common stock on a 2.2-for-1 basis at the closing of the Issuer's initial public\noffering without payment or further consideration and had no expiration date."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"The shares are held directly by Atlas Venture Fund IX, L.P. (\"Atlas Venture Fund IX\"). The general partner of Atlas Venture Fund IX is Atlas\nVenture Associates IX, L.P. (\"AVA IX LP\"). Atlas Venture Associates IX, LLC (\"AVA IX LLC\") is the general partner of AVA IX LP. Each of AVA\nIX LP and AVA IX LLC disclaims Section 16 beneficial ownership of the securities held by Atlas Venture Fund IX, except to the extent of its\npecuniary interest therein, if any."}],"balance_after":4545453,"source":{"system":"sec-edgar","filing":"0001209191-18-025826","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1718108/000120919118025826/doc4.xml","form_type":"4"}},{"id":3973316,"issuer":{"id":3793,"kind":"organization","name":"Cogent Biosciences, Inc.","symbol":"COGT"},"owners":[{"id":144498,"kind":"organization","name":"Atlas Venture Fund IX, L.P.","position":1,"cik":"0001671219","reported_name":"Atlas Venture Fund IX, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":144499,"kind":"organization","name":"Atlas Venture Associates IX, L.P.","position":2,"cik":"0001671208","reported_name":"Atlas Venture Associates IX, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":105946,"kind":"organization","name":"Atlas Venture Associates IX, LLC","position":3,"cik":"0001671207","reported_name":"Atlas Venture Associates IX, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series B Preferred Stock","published_at":"2018-04-03T17:11:15.000Z","date":"2018-04-03","kind":"exercise","acquired":false,"shares":83037,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each share automatically converted into Common Stock, for no additional consideration, on a 1.5701314513884-for-1 basis at the closing of the Issuer's initial public offering. The shares had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Each share automatically converted into Common Stock, for no additional consideration, on a 1.5701314513884-for-1 basis at the closing of the Issuer's initial public offering. The shares had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Each share automatically converted into Common Stock, for no additional consideration, on a 1.5701314513884-for-1 basis at the closing of the Issuer's initial public offering. The shares had no expiration date."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"The shares are held directly by Atlas Venture Fund IX, L.P. (\"Atlas Venture Fund IX\"). The general partner of Atlas Venture Fund IX is Atlas Venture Associates IX, L.P. (\"AVA IX LP\"). Atlas Venture Associates IX, LLC (\"AVA IX LLC\") is the general partner of AVA IX LP. Each of AVA IX LP and AVA IX LLC disclaim Section 16 beneficial ownership of the securities held by Atlas Venture Fund IX, except to the extent of its pecuniary interest therein, if any."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":83037},"source":{"system":"sec-edgar","filing":"0000899243-18-009264","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1671207/000089924318009264/doc4.xml","form_type":"4"}},{"id":3973315,"issuer":{"id":3793,"kind":"organization","name":"Cogent Biosciences, Inc.","symbol":"COGT"},"owners":[{"id":144498,"kind":"organization","name":"Atlas Venture Fund IX, L.P.","position":1,"cik":"0001671219","reported_name":"Atlas Venture Fund IX, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":144499,"kind":"organization","name":"Atlas Venture Associates IX, L.P.","position":2,"cik":"0001671208","reported_name":"Atlas Venture Associates IX, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":105946,"kind":"organization","name":"Atlas Venture Associates IX, LLC","position":3,"cik":"0001671207","reported_name":"Atlas Venture Associates IX, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series A Preferred Stock","published_at":"2018-04-03T17:11:15.000Z","date":"2018-04-03","kind":"exercise","acquired":false,"shares":3184446,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each share automatically converted into Common Stock, for no additional consideration, on a 1.5701314513884-for-1 basis at the closing of the Issuer's initial public offering. The shares had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Each share automatically converted into Common Stock, for no additional consideration, on a 1.5701314513884-for-1 basis at the closing of the Issuer's initial public offering. The shares had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Each share automatically converted into Common Stock, for no additional consideration, on a 1.5701314513884-for-1 basis at the closing of the Issuer's initial public offering. The shares had no expiration date."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"The shares are held directly by Atlas Venture Fund IX, L.P. (\"Atlas Venture Fund IX\"). The general partner of Atlas Venture Fund IX is Atlas Venture Associates IX, L.P. (\"AVA IX LP\"). Atlas Venture Associates IX, LLC (\"AVA IX LLC\") is the general partner of AVA IX LP. Each of AVA IX LP and AVA IX LLC disclaim Section 16 beneficial ownership of the securities held by Atlas Venture Fund IX, except to the extent of its pecuniary interest therein, if any."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":3184446},"source":{"system":"sec-edgar","filing":"0000899243-18-009264","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1671207/000089924318009264/doc4.xml","form_type":"4"}},{"id":3973314,"issuer":{"id":3793,"kind":"organization","name":"Cogent Biosciences, Inc.","symbol":"COGT"},"owners":[{"id":144498,"kind":"organization","name":"Atlas Venture Fund IX, L.P.","position":1,"cik":"0001671219","reported_name":"Atlas Venture Fund IX, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":144499,"kind":"organization","name":"Atlas Venture Associates IX, L.P.","position":2,"cik":"0001671208","reported_name":"Atlas Venture Associates IX, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":105946,"kind":"organization","name":"Atlas Venture Associates IX, LLC","position":3,"cik":"0001671207","reported_name":"Atlas Venture Associates IX, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2018-04-03T17:11:15.000Z","date":"2018-04-03","kind":"purchase","acquired":true,"shares":94052,"price":12,"value":1128624.0,"ownership":{"direct":true},"footnotes":[{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"The shares are held directly by Atlas Venture Fund IX, L.P. (\"Atlas Venture Fund IX\"). The general partner of Atlas Venture Fund IX is Atlas Venture Associates IX, L.P. (\"AVA IX LP\"). Atlas Venture Associates IX, LLC (\"AVA IX LLC\") is the general partner of AVA IX LP. Each of AVA IX LP and AVA IX LLC disclaim Section 16 beneficial ownership of the securities held by Atlas Venture Fund IX, except to the extent of its pecuniary interest therein, if any."}],"balance_after":3361535,"source":{"system":"sec-edgar","filing":"0000899243-18-009264","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1671207/000089924318009264/doc4.xml","form_type":"4"}},{"id":3973313,"issuer":{"id":3793,"kind":"organization","name":"Cogent Biosciences, Inc.","symbol":"COGT"},"owners":[{"id":144498,"kind":"organization","name":"Atlas Venture Fund IX, L.P.","position":1,"cik":"0001671219","reported_name":"Atlas Venture Fund IX, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":144499,"kind":"organization","name":"Atlas Venture Associates IX, L.P.","position":2,"cik":"0001671208","reported_name":"Atlas Venture Associates IX, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":105946,"kind":"organization","name":"Atlas Venture Associates IX, LLC","position":3,"cik":"0001671207","reported_name":"Atlas Venture Associates IX, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2018-04-03T17:11:15.000Z","date":"2018-04-03","kind":"exercise","acquired":true,"shares":83037,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each share automatically converted into Common Stock, for no additional consideration, on a 1.5701314513884-for-1 basis at the closing of the Issuer's initial public offering. The shares had no expiration date."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"The shares are held directly by Atlas Venture Fund IX, L.P. (\"Atlas Venture Fund IX\"). The general partner of Atlas Venture Fund IX is Atlas Venture Associates IX, L.P. (\"AVA IX LP\"). Atlas Venture Associates IX, LLC (\"AVA IX LLC\") is the general partner of AVA IX LP. Each of AVA IX LP and AVA IX LLC disclaim Section 16 beneficial ownership of the securities held by Atlas Venture Fund IX, except to the extent of its pecuniary interest therein, if any."}],"balance_after":3267483,"source":{"system":"sec-edgar","filing":"0000899243-18-009264","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1671207/000089924318009264/doc4.xml","form_type":"4"}},{"id":3973312,"issuer":{"id":3793,"kind":"organization","name":"Cogent Biosciences, Inc.","symbol":"COGT"},"owners":[{"id":144498,"kind":"organization","name":"Atlas Venture Fund IX, L.P.","position":1,"cik":"0001671219","reported_name":"Atlas Venture Fund IX, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":144499,"kind":"organization","name":"Atlas Venture Associates IX, L.P.","position":2,"cik":"0001671208","reported_name":"Atlas Venture Associates IX, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":105946,"kind":"organization","name":"Atlas Venture Associates IX, LLC","position":3,"cik":"0001671207","reported_name":"Atlas Venture Associates IX, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2018-04-03T17:11:15.000Z","date":"2018-04-03","kind":"exercise","acquired":true,"shares":3184446,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each share automatically converted into Common Stock, for no additional consideration, on a 1.5701314513884-for-1 basis at the closing of the Issuer's initial public offering. The shares had no expiration date."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"The shares are held directly by Atlas Venture Fund IX, L.P. (\"Atlas Venture Fund IX\"). The general partner of Atlas Venture Fund IX is Atlas Venture Associates IX, L.P. (\"AVA IX LP\"). Atlas Venture Associates IX, LLC (\"AVA IX LLC\") is the general partner of AVA IX LP. Each of AVA IX LP and AVA IX LLC disclaim Section 16 beneficial ownership of the securities held by Atlas Venture Fund IX, except to the extent of its pecuniary interest therein, if any."}],"balance_after":3184446,"source":{"system":"sec-edgar","filing":"0000899243-18-009264","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1671207/000089924318009264/doc4.xml","form_type":"4"}},{"id":4259119,"issuer":{"id":4585,"kind":"organization","name":"Intellia Therapeutics, Inc.","symbol":"NTLA"},"owners":[{"id":144498,"kind":"organization","name":"Atlas Venture Fund IX, L.P.","position":1,"cik":"0001671219","reported_name":"Atlas Venture Fund IX, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":144499,"kind":"organization","name":"Atlas Venture Associates IX, L.P.","position":2,"cik":"0001671208","reported_name":"Atlas Venture Associates IX, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":105946,"kind":"organization","name":"Atlas Venture Associates IX, LLC","position":3,"cik":"0001671207","reported_name":"Atlas Venture Associates IX, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2017-07-11T17:37:17.000Z","date":"2017-07-11","kind":"sale","acquired":false,"shares":80000,"price":16.0695,"value":1285560.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"Represents shares sold by Atlas Venture Fund IX, L.P. (\"Atlas IX\").  Atlas Venture Associates IX, L.P. (\"AVA IX LP\") is the general partner of Atlas IX.  Atlas Venture Associates IX, LLC (\"AVA IX LLC\") is the general partner of AVA IX LP.  Each of AVA IX LP and AVA IX LLC disclaim Section 16 beneficial ownership of the securities held by Atlas IX, except to the extent of their pecuniary interest therein, if any."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The price reported in Column 4 is a weighted average price.  These shares were sold in multiple transactions at prices ranging from $16.00 - $16.325, inclusive.  The reporting persons undertake to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in footnote (4) of this Form 4."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F5","text":"Represents shares held directly by Atlas IX. The general partner of Atlas IX is AVA IX LP.  AVA IX LLC is the general partner of AVA IX LP. Each of AVA IX LP and AVA IX LLC disclaims Section 16 beneficial ownership of the securities held by Atlas IX, except to the extent of its pecuniary interest therein, if any."}],"balance_after":3579788,"source":{"system":"sec-edgar","filing":"0001104659-17-044529","document":"a4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1671207/000110465917044529/a4.xml","form_type":"4"}},{"id":4259118,"issuer":{"id":4585,"kind":"organization","name":"Intellia Therapeutics, Inc.","symbol":"NTLA"},"owners":[{"id":144498,"kind":"organization","name":"Atlas Venture Fund IX, L.P.","position":1,"cik":"0001671219","reported_name":"Atlas Venture Fund IX, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":144499,"kind":"organization","name":"Atlas Venture Associates IX, L.P.","position":2,"cik":"0001671208","reported_name":"Atlas Venture Associates IX, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":105946,"kind":"organization","name":"Atlas Venture Associates IX, LLC","position":3,"cik":"0001671207","reported_name":"Atlas Venture Associates IX, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2017-07-11T17:37:17.000Z","date":"2017-07-10","kind":"sale","acquired":false,"shares":40000,"price":16.1722,"value":646888.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"Represents shares sold by Atlas Venture Fund IX, L.P. (\"Atlas IX\").  Atlas Venture Associates IX, L.P. (\"AVA IX LP\") is the general partner of Atlas IX.  Atlas Venture Associates IX, LLC (\"AVA IX LLC\") is the general partner of AVA IX LP.  Each of AVA IX LP and AVA IX LLC disclaim Section 16 beneficial ownership of the securities held by Atlas IX, except to the extent of their pecuniary interest therein, if any."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in Column 4 is a weighted average price.  These shares were sold in multiple transactions at prices ranging from $16.00 - $16.70, inclusive.  The reporting persons undertake to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in footnote (3) of this Form 4."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F5","text":"Represents shares held directly by Atlas IX. The general partner of Atlas IX is AVA IX LP.  AVA IX LLC is the general partner of AVA IX LP. Each of AVA IX LP and AVA IX LLC disclaims Section 16 beneficial ownership of the securities held by Atlas IX, except to the extent of its pecuniary interest therein, if any."}],"balance_after":3659788,"source":{"system":"sec-edgar","filing":"0001104659-17-044529","document":"a4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1671207/000110465917044529/a4.xml","form_type":"4"}},{"id":4259117,"issuer":{"id":4585,"kind":"organization","name":"Intellia Therapeutics, Inc.","symbol":"NTLA"},"owners":[{"id":144498,"kind":"organization","name":"Atlas Venture Fund IX, L.P.","position":1,"cik":"0001671219","reported_name":"Atlas Venture Fund IX, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":144499,"kind":"organization","name":"Atlas Venture Associates IX, L.P.","position":2,"cik":"0001671208","reported_name":"Atlas Venture Associates IX, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":105946,"kind":"organization","name":"Atlas Venture Associates IX, LLC","position":3,"cik":"0001671207","reported_name":"Atlas Venture Associates IX, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2017-07-11T17:37:17.000Z","date":"2017-07-07","kind":"sale","acquired":false,"shares":30000,"price":16.7664,"value":502992.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"Represents shares sold by Atlas Venture Fund IX, L.P. (\"Atlas IX\").  Atlas Venture Associates IX, L.P. (\"AVA IX LP\") is the general partner of Atlas IX.  Atlas Venture Associates IX, LLC (\"AVA IX LLC\") is the general partner of AVA IX LP.  Each of AVA IX LP and AVA IX LLC disclaim Section 16 beneficial ownership of the securities held by Atlas IX, except to the extent of their pecuniary interest therein, if any."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price.  These shares were sold in multiple transactions at prices ranging from $16.50 - $17.25, inclusive.  The reporting persons undertake to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in footnote (2) of this Form 4."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F5","text":"Represents shares held directly by Atlas IX. The general partner of Atlas IX is AVA IX LP.  AVA IX LLC is the general partner of AVA IX LP. Each of AVA IX LP and AVA IX LLC disclaims Section 16 beneficial ownership of the securities held by Atlas IX, except to the extent of its pecuniary interest therein, if any."}],"balance_after":3699788,"source":{"system":"sec-edgar","filing":"0001104659-17-044529","document":"a4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1671207/000110465917044529/a4.xml","form_type":"4"}},{"id":4397655,"issuer":{"id":4585,"kind":"organization","name":"Intellia Therapeutics, Inc.","symbol":"NTLA"},"owners":[{"id":144498,"kind":"organization","name":"Atlas Venture Fund IX, L.P.","position":1,"cik":"0001671219","reported_name":"Atlas Venture Fund IX, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":144499,"kind":"organization","name":"Atlas Venture Associates IX, L.P.","position":2,"cik":"0001671208","reported_name":"Atlas Venture Associates IX, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":105946,"kind":"organization","name":"Atlas Venture Associates IX, LLC","position":3,"cik":"0001671207","reported_name":"Atlas Venture Associates IX, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2017-03-07T08:35:00.000Z","date":"2017-03-03","kind":"other","acquired":false,"shares":700000,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"On March 3, 2017, Atlas Venture Fund IX, L.P. (\"Atlas Venture Fund IX\") distributed, for no consideration, 700,000 shares of the Issuer's Common Stock pro-rata to its partners, including its limited partners and its general partner, Atlas Venture Associates IX, L.P. (\"AVA IX LP\"), in accordance with the exemptions afforded by Rule 16a-9 and Rule 16a-13 of the Securities Exchange Act of 1934, as amended (the \"Act\")."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On March 3, 2017, Atlas Venture Fund IX, L.P. (\"Atlas Venture Fund IX\") distributed, for no consideration, 700,000 shares of the Issuer's Common Stock pro-rata to its partners, including its limited partners and its general partner, Atlas Venture Associates IX, L.P. (\"AVA IX LP\"), in accordance with the exemptions afforded by Rule 16a-9 and Rule 16a-13 of the Securities Exchange Act of 1934, as amended (the \"Act\")."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"The shares are held directly by Atlas Venture Fund IX.  Each of AVA IX LP and Atlas Venture Associates IX, LLC, its general partner  (\"AVA IX LLC\") disclaims Section 16 beneficial ownership of the securities held by Atlas Venture Fund IX, except to the extent of its pecuniary interest therein, if any."}],"balance_after":3729788,"source":{"system":"sec-edgar","filing":"0001209191-17-018547","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1671207/000120919117018547/doc4.xml","form_type":"4"}}]}